{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T12:02:37Z","timestamp":1722686557471},"reference-count":37,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1016\/j.pnpbp.2007.06.029","type":"journal-article","created":{"date-parts":[[2007,7,5]],"date-time":"2007-07-05T11:16:35Z","timestamp":1183634195000},"page":"1470-1477","source":"Crossref","is-referenced-by-count":6,"title":["The effectiveness of ziprasidone in treating impaired quality of life in schizophrenia: A 12-month, open-label, flexible-dose, naturalistic observational study of patients undergoing usual care"],"prefix":"10.1016","volume":"31","author":[{"given":"Michael S.","family":"Ritsner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir","family":"Yorkov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yael","family":"Ratner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Soifer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anatoly","family":"Gibel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2007.06.029_bib1","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","article-title":"Antipsychotic-induced weight gain: a comprehensive research synthesis","volume":"156","author":"Allison","year":"1999","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2007.06.029_bib2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1023\/A:1026409326690","article-title":"A conceptual model of quality of life in schizophrenia: description and preliminary clinical validation","volume":"6","author":"Awad","year":"1997","journal-title":"Qual Life Res"},{"key":"10.1016\/j.pnpbp.2007.06.029_bib3","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1600-0447.1996.tb09835.x","article-title":"Quality of life in schizophrenia: relationship to sociodemographic factors, symptomatology and tardive dyskinesia","volume":"94","author":"Browne","year":"1996","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.pnpbp.2007.06.029_bib4","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.schres.2005.02.013","article-title":"Manual for the Extrapyramidal Symptom Rating Scale (ESRS)","volume":"76","author":"Chouinard","year":"2005","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2007.06.029_bib5","first-page":"233","article-title":"Extrapyramidal symptom rating scale","volume":"7","author":"Chouinard","year":"1980","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.pnpbp.2007.06.029_bib6","series-title":"Statistical power analysis for the behavioral sciences","author":"Cohen","year":"1988"},{"key":"10.1016\/j.pnpbp.2007.06.029_bib7","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0893-133X(98)00090-6","article-title":"Ziprasidone 80\u00a0mg\/day and 160\u00a0mg\/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial","volume":"20","author":"Daniel","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2007.06.029_bib8","first-page":"321","article-title":"Quality of life enjoyment and satisfaction questionnaire: a new measure","volume":"29","author":"Endicott","year":"1993","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/j.pnpbp.2007.06.029_bib9","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1034\/j.1600-0447.2001.00254.x","article-title":"Subject and observer-rated quality of life in schizophrenia","volume":"103","author":"Fitzgerald","year":"2001","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.pnpbp.2007.06.029_bib10","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1034\/j.1600-0447.2002.1169.x","article-title":"The EPSILON Study Group. Quality of life in patients with schizophrenia in five European countries: the EPSILON study","volume":"105","author":"Gaite","year":"2002","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.pnpbp.2007.06.029_bib11","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/00004714-199808000-00009","article-title":"An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder","volume":"18","author":"Goff","year":"1998","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2007.06.029_bib12","first-page":"225","article-title":"Objective and subjective quality of life in schizophrenic patients after a first hospitalization","volume":"1","author":"Gorna","year":"2005","journal-title":"Rocz Akad Med Bialymst"},{"key":"10.1016\/j.pnpbp.2007.06.029_bib13","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1023\/A:1016790230228","article-title":"The relationship of personality dimensions as measured by the temperament and character inventory and quality of life in individuals with schizophrenia or schizoaffective disorder living in the community","volume":"10","author":"Hansson","year":"2001","journal-title":"Qual Life Res"},{"key":"10.1016\/j.pnpbp.2007.06.029_bib14","unstructured":"Hintze JL, NCSS 2007. Statistical system for windows. User's guide. Kaysville, 507 Utah: Number Cruncher Statistical Systems; 2006."},{"key":"10.1016\/j.pnpbp.2007.06.029_bib15","doi-asserted-by":"crossref","first-page":"516","DOI":"10.4088\/JCP.v63n0609","article-title":"A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia","volume":"63","author":"Hirsch","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2007.06.029_bib16","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The Positive and Negative Syndrome Scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.pnpbp.2007.06.029_bib17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00004714-200102000-00007","article-title":"Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double-blind, placebo-controlled multicenter trials","volume":"21","author":"Keck","year":"2001","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2007.06.029_bib18","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.eurpsy.2006.06.004","article-title":"Effectiveness, tolerability, and safety of ziprasidone in patients with schizophrenia or schizoaffective disorder: results of a multi-centre observational trial","volume":"22","author":"Kudla","year":"2006","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.pnpbp.2007.06.029_bib21","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000064809","article-title":"Subjective quality of life: its relationship with clinician rated and patient-rated psychopathology. The South-Verona Outcome Project 6","volume":"71","author":"Lasalvia","year":"2002","journal-title":"Psychother Psychosom"},{"key":"10.1016\/j.pnpbp.2007.06.029_bib19","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1007\/s11136-005-3236-6","article-title":"Impact of untreated psychosis on quality of life in patients with first-episode schizophrenia","volume":"14","author":"Law","year":"2005","journal-title":"Qual Life Res"},{"key":"10.1016\/j.pnpbp.2007.06.029_bib20","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1001\/archpsyc.1983.01790040023003","article-title":"The well-being of chronic mental patients: assessing their quality of life","volume":"40","author":"Lehman","year":"1983","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pnpbp.2007.06.029_bib22","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Clinical antipsychotic trials of intervention effectiveness (CATIE) investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Novick","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pnpbp.2007.06.029_bib23","doi-asserted-by":"crossref","first-page":"397","DOI":"10.4088\/JCP.v67n0910","article-title":"The relationship between quality of life and clinical efficacy from a randomized trial comparing olanzapine and ziprasidone","volume":"67","author":"Phillips","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2007.06.029_bib24","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.pnpbp.2007.06.008","article-title":"A 12-month, open-label, flexible-dose, naturalistic observational study of ziprasidone for treating schizophrenia patients undergoing usual care: efficacy and safety","volume":"31","author":"Ratner","year":"2007","journal-title":"Progress in neuro-psychopharmacology and biological psychiatry"},{"key":"10.1016\/j.pnpbp.2007.06.029_bib25","series-title":"Quality of life impairment in schizophrenia, mood and anxiety disorders","first-page":"3","article-title":"The distress\/protection vulnerability model of the quality of life impairment syndrome: current evidence and new directions for research","author":"Ritsner","year":"2007"},{"key":"10.1016\/j.pnpbp.2007.06.029_bib26","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.pnpbp.2006.06.002","article-title":"The effectiveness and predictors of response to antipsychotic agents to treat impaired quality of life in schizophrenia: a 12-month naturalistic follow-up study with implications for confounding factors, antidepressants, anxiolytics, and mood stabilizers","volume":"30","author":"Ritsner","year":"2006","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2007.06.029_bib27","first-page":"173","article-title":"Quality of life impairment syndrome in schizophrenia","author":"Ritsner","year":"2007"},{"key":"10.1016\/j.pnpbp.2007.06.029_bib30","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1023\/A:1016323009671","article-title":"Subjective quality of life measurements in severe mental health patients: measuring quality of life of psychiatric patients: comparison two questionnaires","volume":"11","author":"Ritsner","year":"2002","journal-title":"Qual Life Res"},{"key":"10.1016\/j.pnpbp.2007.06.029_bib29","doi-asserted-by":"crossref","first-page":"880","DOI":"10.4088\/JCP.v61n1113","article-title":"Differences in quality of life domains and psychopathologic and psychosocial factors in psychiatric patients","volume":"61","author":"Ritsner","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2007.06.029_bib31","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1053\/comp.2002.30800","article-title":"Assessing psychological distress in psychiatric patients: validation of the Talbieh Brief Distress Inventory","volume":"43","author":"Ritsner","year":"2002","journal-title":"Compr Psychiatry"},{"key":"10.1016\/j.pnpbp.2007.06.029_bib32","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0924-977X(01)00128-6","article-title":"The impact of side-effects of antipsychotic agents on life satisfaction of schizophrenia patients: a naturalistic study","volume":"12","author":"Ritsner","year":"2002","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.pnpbp.2007.06.029_bib28","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/S0010-440X(95)90253-8","article-title":"The Talbieh Brief Distress Inventory: a brief instrument to measure psychological distress among immigrants","volume":"36","author":"Ritsner","year":"1995","journal-title":"Compr Psychiatry"},{"key":"10.1016\/j.pnpbp.2007.06.029_bib33","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.schres.2005.07.035","article-title":"Antidepressants as add-on treatment to antipsychotics for people with schizophrenia and pronounced negative symptoms: a systematic review of randomized trials","volume":"80","author":"Rummel","year":"2005","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2007.06.029_bib34","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0014-2999(01)01188-8","article-title":"Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile","volume":"425","author":"Schmidt","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pnpbp.2007.06.029_bib35","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1176\/appi.ajgp.11.6.629","article-title":"Functioning and well-being of middle-aged and older patients with schizophrenia: measurement with the 36-item short-form (SF-36) health survey","volume":"11","author":"Sciolla","year":"2003","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.pnpbp.2007.06.029_bib36","first-page":"267","article-title":"Quality of life measurement during antipsychotic drug therapy of schizophrenia","volume":"22","author":"Voruganti","year":"1997","journal-title":"J Psychiatry Neurosci"},{"key":"10.1016\/j.pnpbp.2007.06.029_bib37","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000285058","article-title":"Empirical assessment of the factorial structure of clinical symptoms in schizophrenia. A multisite, multimodel evaluation of the factorial structure of the Positive and Negative Syndrome Scale. The PANSS Study Group","volume":"30","author":"White","year":"1997","journal-title":"Psychopathology"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584607002229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584607002229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T21:29:21Z","timestamp":1683926961000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584607002229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["S0278584607002229"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2007.06.029","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2007,10]]}}}